Skip to main content
Erschienen in: Journal of Cancer Education 6/2018

01.06.2017

Adherence in the Cancer Care Setting: a Systematic Review of Patient Navigation to Traverse Barriers

Erschienen in: Journal of Cancer Education | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Patient navigation is an evidence-based intervention involving trained healthcare workers who assist patients in assessing and mitigating personal and environmental factors to promote healthy behaviors. The purpose of this research is to systematically assess the efficacy of patient navigation and similar programs to improve diagnosis and treatment of diseases affecting medically underserved populations. A systematic review was performed by searching PubMed, MEDLINE, PsychINFO, and CINAHL to identify potential studies. Eligible studies were those containing original peer-reviewed research reports in English on patient navigation, community health workers, vulnerable and underserved populations, and healthcare disparity. Specific outcomes regarding patient navigator including the effect of the intervention on definitive diagnosis and effect on initiation of treatment were extracted from each study. The search produced 1428 articles, and 16 were included for review. All studies involved patient navigation in the field of oncology in underserved populations. Timing of initial contact with a patient navigator after diagnostic or screening testing is correlated to the effectiveness of the navigator intervention. The majority of the studies reported significantly shorter time intervals to diagnosis and to treatment with patient navigation. Patient navigation expedites oncologic diagnosis and treatment of patients in underserved populations. This intervention is more efficacious when utilized shortly after screening or diagnostic testing.
Literatur
1.
Zurück zum Zitat Martin LR, Williams SL, Haskard KB, DiMatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1(3):189–199PubMedPubMedCentral Martin LR, Williams SL, Haskard KB, DiMatteo MR (2005) The challenge of patient adherence. Ther Clin Risk Manag 1(3):189–199PubMedPubMedCentral
2.
Zurück zum Zitat Ferrante JM, Chen P, Kim S (2008) The effect of patient navigation on time to diagnosis, anxiety, and satisfaction in urban minority women with abnormal mammograms: a randomized controlled trial. Journal of Urban Health: Bulletin of the New York Academy of Medicine 85(1):114–124. doi:10.1007/s11524-007-9228-9 CrossRef Ferrante JM, Chen P, Kim S (2008) The effect of patient navigation on time to diagnosis, anxiety, and satisfaction in urban minority women with abnormal mammograms: a randomized controlled trial. Journal of Urban Health: Bulletin of the New York Academy of Medicine 85(1):114–124. doi:10.​1007/​s11524-007-9228-9 CrossRef
3.
Zurück zum Zitat Battaglia TA, Bak S, Heeren T et al (2012) Boston Patient Navigation Research Program: the impact of navigation on time to diagnostic resolution after abnormal cancer screening. Cancer Epidemiol Biomark Prev 21(10):1645–1654. doi:10.1158/1055- 9965.EPI-12-0532 CrossRef Battaglia TA, Bak S, Heeren T et al (2012) Boston Patient Navigation Research Program: the impact of navigation on time to diagnostic resolution after abnormal cancer screening. Cancer Epidemiol Biomark Prev 21(10):1645–1654. doi:10.​1158/​1055- 9965.​EPI-12-0532 CrossRef
5.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman D (2009) Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. Br Med J 338:b2535CrossRef Moher D, Liberati A, Tetzlaff J, Altman D (2009) Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. Br Med J 338:b2535CrossRef
6.
Zurück zum Zitat Oxford Centre for Evidence-based Medicine—levels of evidence (2009). Centre for Evidence-Based Medicine. Retrieved May 4, 2016 Oxford Centre for Evidence-based Medicine—levels of evidence (2009). Centre for Evidence-Based Medicine. Retrieved May 4, 2016
7.
Zurück zum Zitat Percac-Lima S, Ashburner JM, McCarthy AM, Piawah S, Atlas SJ (2015) Patient navigation to improve follow-up of abnormal mammograms among disadvantaged women. J Women’s Health 24(2):138–143. doi:10.1089/jwh.2014.4954 CrossRef Percac-Lima S, Ashburner JM, McCarthy AM, Piawah S, Atlas SJ (2015) Patient navigation to improve follow-up of abnormal mammograms among disadvantaged women. J Women’s Health 24(2):138–143. doi:10.​1089/​jwh.​2014.​4954 CrossRef
8.
Zurück zum Zitat Lee J, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R (2014) Effect of patient navigation on time to diagnostic resolution among patients with colorectal cancer-related abnormalities. J Canc Educ 29:144–150. doi:10.1007/s13187-013-0561-2 CrossRef Lee J, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R (2014) Effect of patient navigation on time to diagnostic resolution among patients with colorectal cancer-related abnormalities. J Canc Educ 29:144–150. doi:10.​1007/​s13187-013-0561-2 CrossRef
9.
Zurück zum Zitat Freund KM, Battaglia TA, Calhoun E et al (2014) Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. JNCI 106(6). doi:10.1093/jnci/dju115 Freund KM, Battaglia TA, Calhoun E et al (2014) Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. JNCI 106(6). doi:10.​1093/​jnci/​dju115
10.
Zurück zum Zitat Bensink ME, Ramsey SD, Battaglia T et al (2014) Costs and outcomes evaluation of patient navigation after abnormal cancer screening. Cancer:570–578. doi:10.1002/cncr.28438 Bensink ME, Ramsey SD, Battaglia T et al (2014) Costs and outcomes evaluation of patient navigation after abnormal cancer screening. Cancer:570–578. doi:10.​1002/​cncr.​28438
11.
Zurück zum Zitat Lee J, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R (2013) Patient navigation and time to diagnostic resolution: results for a cluster randomized trial evaluating the efficacy of patient navigation among patients with breast cancer screening abnormalities, Tampa, FL. PLoS One 8(9):e74542. doi:10.1371/journal.pone.0074542 CrossRefPubMedPubMedCentral Lee J, Fulp W, Wells KJ, Meade CD, Calcano E, Roetzheim R (2013) Patient navigation and time to diagnostic resolution: results for a cluster randomized trial evaluating the efficacy of patient navigation among patients with breast cancer screening abnormalities, Tampa, FL. PLoS One 8(9):e74542. doi:10.​1371/​journal.​pone.​0074542 CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Dudley DJ, Drake J, Quinlan J et al (2012) Beneficial effects of a combined navigator/promotora approach for Hispanic women diagnosed with breast abnormalities. Cancer Epidemiol Biomark Prev 21(10):1639–1644. doi:10.1158/1055- 9965.EPI-12-0538 CrossRef Dudley DJ, Drake J, Quinlan J et al (2012) Beneficial effects of a combined navigator/promotora approach for Hispanic women diagnosed with breast abnormalities. Cancer Epidemiol Biomark Prev 21(10):1639–1644. doi:10.​1158/​1055- 9965.​EPI-12-0538 CrossRef
13.
Zurück zum Zitat Markossian TW, Darnell JS, Calhoun EA (2012) Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program. Cancer Epidemiol Biomark Prev 21(10):1691–1700. doi:10.1158/1055- 9965.EPI-12-0535 CrossRef Markossian TW, Darnell JS, Calhoun EA (2012) Follow-up and timeliness after an abnormal cancer screening among underserved, urban women in a patient navigation program. Cancer Epidemiol Biomark Prev 21(10):1691–1700. doi:10.​1158/​1055- 9965.​EPI-12-0535 CrossRef
14.
Zurück zum Zitat Paskett E, Katz ML, Douglas MP et al (2012) The ohio Patient Navigation Research Program (OPNRP): does the American Cancer Society patient navigation model improve time to resolution among patients with abnormal screening tests? Cancer Epidemiol Biomark Prev 21(10):1620–1628. doi:10.1158/1055-9965.EPI-12-0523 CrossRef Paskett E, Katz ML, Douglas MP et al (2012) The ohio Patient Navigation Research Program (OPNRP): does the American Cancer Society patient navigation model improve time to resolution among patients with abnormal screening tests? Cancer Epidemiol Biomark Prev 21(10):1620–1628. doi:10.​1158/​1055-9965.​EPI-12-0523 CrossRef
15.
Zurück zum Zitat Raich PC, Whitley EM, Thorland W, Valverde P, Fairclough D (2012) Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomark Prev 21(10):1629–1638. doi:10.1158/1055-9965.EPI-12-0513 CrossRef Raich PC, Whitley EM, Thorland W, Valverde P, Fairclough D (2012) Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomark Prev 21(10):1629–1638. doi:10.​1158/​1055-9965.​EPI-12-0513 CrossRef
16.
Zurück zum Zitat Wells KJ, Lee J, Calcano E et al (2012) A cluster randomized trial evaluating the efficacy of patient navigation in improving quality of diagnostic care for patients with breast or colorectal cancer abnormalities. Cancer Epidemiol Biomark Prev 21(10):1664–1672. doi:10.1158/1055-9965.EPI-12-0448 CrossRef Wells KJ, Lee J, Calcano E et al (2012) A cluster randomized trial evaluating the efficacy of patient navigation in improving quality of diagnostic care for patients with breast or colorectal cancer abnormalities. Cancer Epidemiol Biomark Prev 21(10):1664–1672. doi:10.​1158/​1055-9965.​EPI-12-0448 CrossRef
18.
Zurück zum Zitat Ell K, Vourlekis B, Muderspach L et al (2002) Abnormal cervical screen follow-up among low-income Latinas: project safe. J Women’s Health Gend-Based Med 11(7):639–651CrossRef Ell K, Vourlekis B, Muderspach L et al (2002) Abnormal cervical screen follow-up among low-income Latinas: project safe. J Women’s Health Gend-Based Med 11(7):639–651CrossRef
19.
Zurück zum Zitat Ramirez A, Perez-Stable E, Penedo F et al (2014) Reducing time-to-treatment in underserved Latinas with breast cancer. Cancer:752–760. doi:10.1002/cncr.28450 Ramirez A, Perez-Stable E, Penedo F et al (2014) Reducing time-to-treatment in underserved Latinas with breast cancer. Cancer:752–760. doi:10.​1002/​cncr.​28450
20.
Zurück zum Zitat Ell K, Padgett D, Vourlekis B et al (2002) Abnormal mammogram follow-up: a pilot study in women with low income. Cancer Pract 10(3):130–138CrossRefPubMed Ell K, Padgett D, Vourlekis B et al (2002) Abnormal mammogram follow-up: a pilot study in women with low income. Cancer Pract 10(3):130–138CrossRefPubMed
23.
Zurück zum Zitat Dolly D, Mihai A, Rimel BJ et al (2016) A delay from diagnosis to treatment is associated with decreased overall survival for patients with endometrial cancer. Front Oncol 12(6):31. doi:10.3389/fonc.2016.00031 CrossRef Dolly D, Mihai A, Rimel BJ et al (2016) A delay from diagnosis to treatment is associated with decreased overall survival for patients with endometrial cancer. Front Oncol 12(6):31. doi:10.​3389/​fonc.​2016.​00031 CrossRef
24.
Zurück zum Zitat Gilbert JE, Green E, Lankshear S et al (2011) Nurses as patient navigators in cancer diagnosis: review, consultation and model design. Eur J Cancer Care 20:228–236CrossRef Gilbert JE, Green E, Lankshear S et al (2011) Nurses as patient navigators in cancer diagnosis: review, consultation and model design. Eur J Cancer Care 20:228–236CrossRef
Metadaten
Titel
Adherence in the Cancer Care Setting: a Systematic Review of Patient Navigation to Traverse Barriers
Publikationsdatum
01.06.2017
Erschienen in
Journal of Cancer Education / Ausgabe 6/2018
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-017-1235-2

Weitere Artikel der Ausgabe 6/2018

Journal of Cancer Education 6/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.